Vizsgálati helyszín
Rheuma Medicus Sp z o o
Warsaw, 02 118, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 19futó vizsgálat
- 12lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 32 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis23 vizsgálat
- 2. fázis6 vizsgálat
- 4. fázis3 vizsgálat
- Állapot
- Lezárult12 vizsgálat
- Fut, nem toboroz11 vizsgálat
- Még nem toboroz4 vizsgálat
- Toboroz4 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC5 vizsgálat
- MoonLake Immunotherapeutics AG3 vizsgálat
- Novartis Pharmaceuticals3 vizsgálat
- Sun Pharmaceutical Industries Limited3 vizsgálat
- Alumis Inc2 vizsgálat
- és még 14
Futó vizsgálatok
Még nem toboroz
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis
2026-526538-15-00· 3. fázis· Celltrion Inc.· Forrás
Még nem toboroz
A Trial of LAD603 in Patients with Systemic Lupus Erythematosus
2026-527200-24-00· 2. fázis· Almirall S.A.· Forrás
Toboroz
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· 3. fázis· Takeda· Forrás
Még nem toboroz
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
2025-524005-32-00· 2. fázis· Elevara Medicines Limited· Forrás
Toboroz
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· 3. fázis· Janssen Research & Development, LLC· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.
2024-516219-25-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· 3. fázis· Takeda· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Toboroz
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
NCT06454188· 4. fázis· CARE ARTHRITIS LTD.· Forrás
Fut, nem toboroz
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
2022-500699-76-00· 3. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Fut, nem toboroz
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
NCT04963296· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210· 4. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159· 3. fázis· AbbVie· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
2023-506664-14-00· 3. fázis· Dr Reddy's Laboratories Limited· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
NCT06624228· 3. fázis· UCB Biopharma SRL· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
NCT06586112· 3. fázis· Alumis Inc· Forrás
Lezárult
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis
2023-504564-42-00· 2. fázis· Anaptysbio Inc.· Forrás
Lezárult
Safety and Efficacy of RHH646 for Knee Osteoarthritis
NCT05816395· 2. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis
2022-501425-20-00· 2. fázis· Eli Lilly & Co.· Forrás
Lezárult
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
NCT05767034· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
2024-512142-42-00· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Lezárult
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
NCT04936308· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544· 3. fázis· Sun Pharmaceutical Industries Limited· Forrás
Lezárult
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
NCT03915964· 4. fázis· Eli Lilly and Company· Forrás
Hibát jelzek